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ABSTRACT
PMN-expressed fucosylated glycans from the Lewis
glycan family, including Lewis-x (Lex) and sialyl Lewis-x
(sLex), have previously been implicated in the regulation
of important PMN functions, including selectin-mediated
trafficking across vascular endothelium. Although gly-
cans, such as Lex and sLex, which are based on the type
2 sequence (Galb1-4GlcNAc-R), are abundant on PMNs,
the presence of type 1 Galb1-3GlcNAc-R glycans re-
quired for PMN expression of the closely related ste-
reoisomer of Lex, termed Lewis-A (Lea), has not, to our
knowledge, been reported. Here, we show that Lea is
abundantly expressed by human PMNs and functionally
regulates PMN migration. Using mAbs whose precise
epitopes were determined using glycan array technol-
ogy, Lea function was probed using Lea-selective mAbs
and lectins, revealing increased PMN transmigration
acrossmodel intestinal epithelia, whichwas independent
of epithelial-expressed Lea. Analyses of glycan synthetic
machinery in PMNs revealed expression of b1-3 galac-
tosyltransferase and a1–4 fucosyltransferase, which are
required for Lea synthesis. Specificity of functional ef-
fects observed after ligation of Lea was confirmed by
failure of anti-Lea mAbs to enhance migration using
PMNs from individuals deficient in a1–4 fucosylation.
These results demonstrate that Lea is expressed on
human PMNs, and its specific engagement enhances
PMN migration responses. We propose that PMN Lea
represents a new target for modulating inflammation and
regulating intestinal, innate immunity. J. Leukoc. Biol.
102: 753–762; 2017.
Introduction
PMNs are critical, innate immune cells, which are essential for
successful elimination of invading pathogens. PMNs also have an
important role in wound healing and restitution of mucosal
homeostasis at later stages of the inflammatory response.
However, dysregulated or excessive PMN influx can result in
bystander tissue damage, which is pathognomonic of numerous
mucosal inflammatory disorders. During inflammation/
infection, circulating PMNs exit the microcirculation through a
sequential extravasation cascade that encompasses PMN capture,
rolling, activation, adhesion, and intraluminal crawling [1].
It is well documented that some ligand-receptor recognition
interactions during PMN extravasation are controlled by post-
translational glycosylation modifications. For example, glycans on
P-selectin glycoprotein ligand 1 have a key role in regulating
PMN rolling on the vascular endothelium during inflammatory
responses in vivo. The glycans of P-selectin glycoprotein ligand 1
have been extensively studied, and several key glycan modifica-
tions (including a1,3 fucosylation, a2,3 sialylation, and b1,4
galactosylation) have been identified as being important for
mediating PMN capture and endothelial rolling [2]. In addition,
endothelial P-selectin and E-selectin contain binding sites for
PMN fucose, containing Lewis family glycans, including sLex
[Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb-R] and Lex [Galb1-4
(Fuca1-3)GlcNAcb-R] [3].
Following extravasation, PMNs must migrate through the
interstitium and basement membranes before crossing epithelial
barriers that line organs such as the lungs and intestine.
Although the role of glycan-binding interactions in mediating key
steps in PMN transendothelial migration is well accepted, much
less is known about the role of glycans once PMNs have exited
the microcirculation to undergo the process of migration into
epithelial-lined organs. We recently showed that targeting glycans
terminating in sLea [Neu5Aca2-3Galb1-3(Fuca1-4)GlcNAcb-R]
on the apical, epithelial glycoprotein CD44v6 prevents shedding
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of the CD44v6 extracellular domain and results in PMN
accumulation on the apical (luminal) epithelial surface [4, 5].
Similarly, targeting of the related Lewis family member Lex,
which is selectively expressed on PMN but not epithelial cells,
also inhibits PMN TEM [6].
Despite the importance of Lewis glycans in facilitating both
PMN transendothelial migration and PMN trafficking across
mucosal epithelium, several Lewis glycans, including Lea have yet
to be examined in the context of PMN trafficking. Lea is a blood
group Ag glycan, which is usually attached at the nonreducing
ends of glycoconjugates and has a role both in cell–cell
communication and cell adhesion [7–11]. Further, although
Lewis glycans based on the type 2 Lewis sequence (Galb1-
4GlcNAc-R), including Lex, are abundantly expressed on PMNs,
the presence of type 1 Galb1-3GlcNAc-R glycans, which are
required for the expression of Lea by PMNs, has not yet, to our
knowledge, been investigated.
Here, we show that human PMNs express the glycosyltrans-
ferases necessary for Lea synthesis as well as multiple glycopro-
teins containing terminal Lea glycan structures. Importantly,
specific mAb and lectin targeting of Lea increases PMN
transepithelial migration, thus demonstrating an important
(novel) role for this glycan during PMN intestinal trafficking.
MATERIALS AND METHODS
Antibodies and reagents
Anti-Lea mAb clone 7LE, anti-CD18 mAb, anti-Fut3 mAb, anti-b3GalT1 mAb,
and anti-b3GalT4 mAb were purchased from Abcam Inc. (Cambridge, MA,
USA). A second anti-Lea mAb (clone SPM 522) was purchased from Thermo
Fisher Scientific (Waltham, MA, USA). Antitubulin mAb, Lea trisaccharide,
and fMLF were purchased from Sigma-Aldrich (St. Louis, MO, USA). Anti-Lex
mAb clones H198 and W6D3 were purchased from BD Biosciences (Franklin
Lakes, NJ, USA). The anti-CD11b Ab CBRM1/29 and the anti-JAMA mAb
J10.4 have been characterized elsewhere [12, 13]. IL-8 and recombinant
human MBL were purchased from R&D Systems (Minneapolis, MN, USA).
PNGaseF was purchased from New England BioLabs (Ipswich, MA, USA).
Primers for Fuc-T3, b3GalT1, b3GalT4, and MBP were purchased from
OriGene Technologies (Rockville, MD, USA). Primers for GAPDH were
purchased from Integrated DNA Technologies (Coralville, IA, USA). Poly-
morphprep was purchased from Axis-Shield (Alere Technologies, Oslo, Norway).
Cell culture and PMN isolation
Cultures of T84 and Caco2 IECs (passages 63–68) were grown, as previously
described [5, 14]. HL60 cells were obtained from the ATCC (Rockville, MD,
USA) and were passaged in RPMI-1640 medium containing 20% heat-
inactivated FBS (Atlanta Biologicals, Flowery Branch, GA, USA) with
supplements and differentiated with DMSO, as described previously [15].
PMNs were isolated from whole blood obtained from healthy human
volunteers, with approval from the Emory University and University of
Michigan institutional review boards on human subjects, using a previously
described density-gradient centrifugation technique [4]. Briefly, whole blood
was layered onto Polymorphprep (Alere Technologies) at a ratio of 1:1 and
centrifuged at 500 g for 50 min. The PMN-containing layer was carefully
collected, and any contaminating erythrocytes were removed by lysis with ice-
cold, sterile water. PMNs were then resuspended in HBSS with 10 mM HEPES,
pH 7.4, and without Ca2+ or Mg2+, at a concentration of 5 3 107 cells/ml.
PMNs isolated in this way were 97% pure and .95% viable and were used for
all assays within 2 h of blood draw. For analysis of PMN gene transcription,
eosinophils were removed from isolated PMNs using the Human Eosinophil
Isolation kit (Miltenyi Biotec, San Diego, CA, USA) according to the
manufacturer’s protocol.
Characterization of Lewis blood group status among
RBC donors
Whole blood was isolated from healthy donors via venipuncture into a
standard adenine, citrate, and dextrose solution used to immunophenotype
an individual’s blood group status. A 3% hematocrit solution was then
prepared and incubated with monoclonal anti-Lea or anti-Leb (Immucor,
Norcross, GA, USA) using standard blood bank practices. Briefly, RBCs were
incubated with anti-Lea, anti-Leb, or no Ab for 20 min at room temperature,
followed by centrifugation at 300 g. Cells were then evaluated under a
microscope for agglutination. Positive agglutination reactions are used to
determine Ag positivity. All experiments were conducting using Emory
institutional review board–approved procedures.
Analysis of mAb specificity by glycan microarray assay
The anti-Lea Ab 7LE was submitted to the CFG (http://www.functionalgly-
comics.org; Scripps Research Institute, San Diego, CA, USA) at 2 mg/ml
and screened for glycoepitope binding using the version 5.1 glycan array
(CFG). This glycan microarray contains 610 individual glycans printed on
activated glass slides, representing a library of known, natural and synthetic,
mammalian glycans, in replicates of 6. After washing, binding of Abs to
specific glycan epitopes was detected with Alexa Fluor 488–labeled goat anti-
mouse IgG (Thermo Fisher Scientific) as described previously [5, 16]. The
RFUs of the bound Ab–glycan complexes were detected on a PerkinElmer
(Waltham, MA, USA) ProScanArray 4 laser scanner and quantified using
ImaGene software (BioDiscovery, El Segundo, CA, USA).
Immunoblotting and protein purification
PMN cell lysates for immunoblotting were prepared with the following
lysis buffer (20 mM Tris, pH 7.5; 150 mM NaCl; 1 mM EDTA; 1% TX-100;
1 mM Na3VO4; and 1 mM PMSF) supplemented with 10% mammalian
tissue protease inhibitor cocktail (Sigma-Aldrich). PMN cell lysates were
boiled in SDS-PAGE sample buffer under reducing conditions, and then
subjected to SDS-PAGE followed by transfer to PVDF under standard
conditions. Membranes were blocked with 4% milk powder or 3% BSA
and incubated with 1 mg/ml of indicated mAb. Primary Ab binding was
detected using appropriate HRP-linked secondary Abs (Jackson
ImmunoResearch Laboratories, West Grove, PA, USA). N-glycans were
removed from PMN protein lysate PNGaseF, according to manufacturer’s
instructions. Immunoblots are representative of PMNs isolated from 5
independent donors. Functionally active, human CD11b/CD18 was
purified from PMNs by LM2/1 immunoaffinity chromatography as
described previously [3, 17] and immunoblotted using anti-Lex, anti-Lea,
anti-CD18, and anti-CD11b mAbs.
PMN and intestinal epithelial cell immunostaining
Isolated PMNs were fixed with 3.7% paraformaldehyde and, where indicated,
permeabilized with 0.5% Triton-X. After blocking with 3% BSA, PMNs were
incubated with 10 mg/ml of the indicated Abs. After washing, PMNs were
incubated with an FITC-labeled secondary Ab and mounted in ProLong
antifading embedding solution (Thermo Fisher Scientific). Nuclei were
visualized by staining with TO-PRO-1 (Thermo Fisher Scientific). Images
shown are representative of PMN from $3 independent PMN donors with
multiple images captured per donor.
Immunofluorescent labeling of IECs was achieved as follows. T84 and Caco2
monolayers were fixed using methanol and, subsequently, blocked with 3%
BSA. Monolayers were then incubated with primary Abs (10 mg/ml) and
fluorescently labeled secondary Abs. After Ab incubations, IECs were mounted in
ProLong antifading embedding solution. Images shown are representative of $3
experiments with multiple images taken per monolayer using a Leica Inverted
SP5 Confocal Microscope System (Leica Biosystems, Bannockburn, IL, USA).
PMN transmigration assays
For transepithelial migration experiments, IECs were grown on collagen-
coated, permeable, 0.33-cm2, polycarbonate filters (5 mm pore size; CoStar
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Group, Washington DC, USA), as described previously [4, 14, 18]. All
epithelial migration experiments were performed in the physiologically
relevant basolateral-to-apical direction (i.e., inverted monolayers), in the
presence of a chemotactic gradient of 100 nM fMLF. For migration
experiments, 1 3 106 PMNs pretreated with 10 mg/ml of the indicated
Abs, lectins, or soluble Lewis A trisaccharide were added to the upper
chambers of transwell inserts and migration was measured at 37°C for 1 h.
Transmigrated PMNs were quantified by assaying for the PMN azurophilic
marker myeloperoxidase, as published previously [18]. Briefly, Triton
X-100 was added to the lower reservoir of the transwell (final concentra-
tion 0.5%), and the pH was adjusted to 4.2 with citrate buffer. For each
sample, color development was assayed at 405 nm on a microtiter plate
reader after mixing equal parts of sample and a solution containing 1 mM
2,29-azino-di-(3-ethyl)dithiazoline sulfonic acid and 10 mM H2O2 in
100 nM citrate buffer pH 4.2. The assay was standardized with known
dilutions of the same PMNs used in each experiment and was linear in the
range used (0.05 3 106–1 3 106 PMNs). The percentage of migration
represents the percentage of the 1 3 106 PMNs added (for each sample)
to the upper portion of the transwell system. For PMN chemotaxis assays,
PMNs were incubated with 10 mg/ml of the indicated Abs, lectins, or
soluble Lewis A trisaccharides before migration across collagen-coated,
permeable, 0.33-cm2, polycarbonate filters to 100 nm fMLF, or 100 nM
IL-8 was assessed by measurement myeloperoxidase, as described above.
Data are means 6 SE (n = 5).
Flow cytometry and phagocytosis analyses
For flow cytometry analyses, nonstimulated PMNs or PMNs stimulated
with 10 nM fMLF were blocked in 3% BSA with Human TruStain FcX
(FC Receptor Blocking Solution; BioLegend, San Diego, CA, USA)
before incubation with 10 mg/ml anti-Lea mAb, 10 mg/ml anti-CD11b
mAb, 10 mg/ml anti-Lex mAb, or an IgG isotype-matched control mAb.
Following primary Ab incubation, PMNs were washed and incubated with
relevant, fluorescently labeled, secondary mAbs and fixed in 3.7%
paraformaldehyde, before analysis by flow cytometry. Flow cytometric
analysis was carried out using a FACScan (Becton Dickinson, Franklin
Lakes, NJ, USA), equipped with an argon ion laser tuned at a 488-nm
wavelength. Data are representative of PMNs isolated from 3–5 healthy
donors. For analysis of changes in surface expression of Lex and CD18/CD11b,
PMNs were incubated with 10 mg/ml anti-Lea mAb (7LE), 10 mg/ml isotype
matched control mAb, or 10 nm fMLF, before blocking in 3% BSA with Human
TruStain FcX and subsequent incubation with 10 mg/ml FITC-labeled anti-Lex
and FITC-labeled anti-CD11b mAbs. For phagocytosis assays, PMNs were
incubated with 10 mg/ml relevant Abs and FITC-conjugated FluoSpheres
(Thermo Fisher Scientific) at a ratio of 1:100 (PMN to FluoSpheres) in the
presence of 10 nM fMLF, 10 mg/ml anti-Lea mAb (7LE), 10 mg/ml IgG isotype-
matched control mAb, or 10 mg/ml MBL for 30 min at 37°C. Uptake of
FluoSpheres by PMNs was assessed by flow cytometry using an argon laser tuned
at a 488-nm wavelength.
Transcriptional analysis
HL60 cells or human PMNs were lysed in TRIzol (Thermo Fisher Scientific)
then subjected to phenol-chloroform extraction, according to the manufac-
turer’s protocol [19]. RNA was digested with DNaseI (Ambion, Austin, TX,
USA) to remove contamination with genomic DNA; then, DNA was
synthesized by reverse transcription using oligo(dt12–18) primers and
Superscript II reverse transcriptase (Thermo Fisher Scientific). Real-time PCR
was performed with a MyIQ real-time PCR machine and SYBR Green
supermix (Bio-Rad Laboratories, Hercules, CA, USA). Data were analyzed by
the DDCt threshold cycle method and normalized to the housekeeping gene
GAPDH. Data are means 6 SE from 5 healthy blood donors (n = 5).
Data analysis
Statistical differences were determined by 2-factor ANOVA using PRISM 5 for
Mac OSX (version 5.0a 1992–1998; GraphPad Software, La Jolla, CA, USA).
Values are expressed as the means 6 SE from $3 separate experiments.
RESULTS
PMNs express the type 1 glycan Lea
Although it has been widely reported that PMNs express type 2
Lewis glycans, including Lex and sLex, abundantly [6, 20], and
that these glycans regulate important functions, including
migration, phagocytosis, and degranulation, it is not known
whether PMNs express the type 1 Lewis glycan Lea (Fig. 1A) and
what its function might be. Immunoblotting of lysates from
human PMNs revealed expression of several large Lea glycans
containing glycoproteins between 100 and 250 kDa (Fig. 1B). To
determine whether PMN-expressed Lea was displayed as part of
larger N- or O-linked glycan structures, PMN lysates were treated
with PNGaseF, an N-glycosidase that cleaves all types of
asparagine-bound N-glycans. As shown in Fig. 1C, PNGaseF
treatment prevented detection of PMN Lea by immunoblotting,
suggesting that this trisaccharide is displayed as part of larger
N-linked PMN glycan structures.
Surface expression of Lea on PMNs was confirmed by
immunofluorescence staining and flow cytometry (Fig. 1D and
E). No increase in expression of Lea was observed after
stimulation with 10 nm fMLF (Fig. 1E and F). As a positive
control for fMLF-mediated PMN activation, surface expression of
the b2 integrin CD18/CD11b was also measured. In contrast to
the unchanging expression of Lea, there was a significant
increase in surface expression of CD18/CD11b after PMN
activation with fMLF (Fig. 1E and F; ***P . 0.001) suggesting
that PMN Lea glycans are displayed on proteins other than
CD18/CD11b. Additional confirmation of PMN Lea expression
was obtained by immunohistochemical analysis of human tissue
sections containing inflamed and noninflamed intestinal mu-
cosa. In addition to the expected expression of Lea on intestinal
epithelial cells [21, 22], expression of Lea was also observed on
circulating PMNs in noninflamed tissue as well as on infiltrating
PMNs in the intestinal mucosa of individuals with ulcerative
colitis (Fig. 1G).
Binding specificity of anti-Lea mAb 7LE
To exclude the possibility of nonspecific binding of anti-Lea
mAbs to the closely related PMN-expressed Lewis glycan
stereoisomer Lex, glycan array analyses were performed. Such
analyses afford identification of highly specific presentations of
Lea glycans recognized by anti-Lea mAbs at a molecular/
structural level. The anti-Lea mAb 7LE was assayed for binding to
a panel of 610 mammalian glycan structures using the version 5.1
glycan microarray from the CFG. Analyses revealed that 7LE
bound with highest affinity to glycans expressing Galb1-3(Fuca1-
4)GlcNAc (Lea), in which the Lea structure was expressed in a
terminal, nonreducing position (13,115 RFU, glycan 127; Fig. 2).
The 7LE also recognized glycans containing terminal Lea
determinants in repeating poly-Lea structures (2502 RFU, glycan
278). Importantly, there was no recognition by the anti-Lea mAb
of the stereoisomer glycan structure Lex (glycan 152; Fig. 2).
Further, 7LE showed no binding to glycans containing only an
internal Lea sequence (glycans 395, 473, Supplemental Fig. 1).
Interestingly, 7LE also failed to recognize glycans terminating
with the sialylated version of Lea (sLea) (glycans 240, 331, 239).
Taken together, these results highlight the highly restricted and
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Figure 1. Human PMN express N-glycan-linked Lea. (A) Schematic of Lea trisaccharide glycan. (B) Immunoblot of lysates from human PMNs
showing expression of multiple Lea-containing glycoproteins. Data shown are representative of blotting from PMNs isolated from 5 independent
donors. (C) Treatment with PNGaseF removes N-glycan–linked Lea from human PMN glycoproteins. Data shown are representative of blotting from
PMNs isolated from 5 independent donors. (D) Immunofluorescence showing expression of Lea in permeabilized human PMNs with Lea in green
and CD18/CD11b in red. Data shown are representative of imaging from PMNs isolated from 5 independent donors. (E) Representative flow plots
(continued on next page)
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differential recognition of discrete, terminal Lea glycan struc-
tures by the anti-Lea mAb 7LE.
PMNs express glycosyltransferases required for Lea
biosynthesis
Having demonstrated specific recognition of Lea by the anti-Lea
mAb 7LE, as well as Lea expression by human PMNs, we next
examined changes in expression of glycosyltransferases required
for generation of Lea, including an a1-4 fucosyltransferase and
a b1-3 galactosyltransferase [23] (Fig. 3A) in ND vs. Dif HL60
cells. Interestingly, increased expression of the a1,4 fucosyl-
transferase FUT3 as well as the galactosyltransferase b3Galt1 was
observed when HL60 cells were Dif toward a PMN-like state
(Fig. 3B). These differences in expression were further quanti-
fied by real-time PCR. Analyses revealed an 80-fold increase in
the expression of FUT3 (***P , 0.001), a 90-fold increase in the
expression of b3Galt1 (*** P , 0.001), and a 30-fold increase
in the expression of b3Galt4 (*** P , 0.001) in Dif HL60
cells relative to ND HL60 cells (Fig. 3C). Analysis of protein
expression revealed a similar increase in the expression of FUT3
and b3Galt4 upon HL60 differentiation (Fig. 3D). Analysis of
gene expression in human PMNs confirmed expression of the
a1,4 fucosyltransferase FUT3 as well as the galactosyltransferase
b3Galt4 (Fig. 3E). However, in contrast to Dif HL60 cells, no
expression of b3Galt1 was observed in human PMNs (Fig. 3E).
The absence of contaminating eosinophils in PMN cDNA
samples was confirmed by the lack of expression of the
eosinophil marker MBP. Robust protein expression of both
FUT3 and b3Galt4 was observed in PMNs from 5 healthy donors
(Fig. 3F).
Selective targeting of Lea increases PMN migration
Glycan mediated-binding interactions have previously been
shown to have a role in PMN trafficking across both endothelial
and epithelial barriers [2, 3, 5, 6]. Therefore, we next examined
the role of Lea in regulating PMN TEMs. As shown in Fig. 4A,
specific mAb engagement of terminal Lea glycans with the
anti-Lea mAb 7LE (10 mg/ml) resulted in a significant increase in
PMN TEMs across T84 IECs relative to PMN treated with no
mAbs or with 10 mg/ml J10.4, an IgG matched-binding
control mAb (***P , 0.001). A similar increase in PMN TEMs
was observed after incubation of PMN with 10 mg/ml of a
second anti-Lea mAb (SPM522; ***P , 0.001). In addition,
targeting of Lea with 1 of its physiologic ligands (MBL, 10 mg/ml)
also increased PMN TEMs relative to treatment with a non-Lea
binding lectin (Tomato lectin, ***P , 0.001, 10 mg/ml).
Specificity of MBL and anti-Lea mAbs for Lea was demonstrated
by incubating PMNs with 10 mg/ml anti-Lea mAbs/lectins in
the presence of soluble Lea trisaccharide (10 mg/ml). As
shown in Fig. 4A, incubation with soluble Lea trisaccharide
prevented all mAb/lectin-mediated increases in PMN
trafficking.
To confirm that anti-Lea mAbs/MBL were specifically
targeting PMN-expressed Lea, expression of Lea in T84 and
Caco2 IECs were next examined. Western blotting revealed
robust expression of numerous Lea-containing glycoproteins by
T84 IECs. In contrast, there was no detectable expression of
Lea-containing glycans in Caco2 IECs (Fig. 4B). Confocal
microscopy analyses (Fig. 4C) confirmed the lack of expression
of Lea in Caco2 IECs and revealed non tight junction
associated, apical expression of Lea in T84 IECs. Further, the
showing surface expression of Lea and CD118/CD11b on nonstimulated (Ntx) PMNs (blue) and 10-nm fMLF-treated PMNs (red) relative to an IgG
control (gray). (F) Quantification of changes in surface expression of Lea and CD18/CD11b after stimulation with fMLF. Data expressed as mean
fluorescence intensity are means6 SE from n = 5 independent blood donors. ***P, 0.001. (G) Immunohistochemistry demonstrating expression of Lea
on circulating PMNs and on PMNs in the inflamed intestinal mucosa of individuals with ulcerative colitis (original magnifications,320 and340). Images
are representative of tissue extracted from n = 3 human tissue samples.
Figure 2. Glycan array analysis demonstrating
exquisite specificity of an anti-Lea mAb 7LE. The
mAb 7LE (2 mg/ml) was incubated with an array
of 610 glycan structures (version 5.1 glycan micro-
array; CFG) and detected with Alexa Fluor-488–
labeled anti-mouse IgG. As shown, 7LE specifically
recognized glycans terminating in Lea. ND, not
detectable (,500 RFU); SP, spacer.
Brazil et al. Targeting of PMN Lea increases PMN trafficking
www.jleukbio.org Volume 102, September 2017 Journal of Leukocyte Biology 757
lack of Lea expression on Caco2 IECs did not prevent the
increase in PMN TEMs observed downstream of the ligation of
Lea by anti-Lea mAbs or MBL (***P , 0.001, Fig. 4D),
suggesting that it is Lea expressed on PMN that is crucial
for mediating the enhanced transepithelial migration. The
effects of directly targeting PMN Lea on PMN trafficking were
also studied in transmigration assays, where PMNs migrate
across acellular, collagen-coated transwell filters. These
data demonstrate that targeting of PMN-expressed Lea with
10 mg/ml anti-Lea mAbs (7LE and SPM522) and 10 mg/ml
MBL results in enhanced transmigration across collagen
to both fMLF and IL-8 (**P . 0.01, ***P . 0. 001, Fig. 4E
and F).
Specificity of Lea glycans in mediating observed increases in
PMN migration was confirmed in transmigration experiments
with PMN derived from human donors that lack Lea. Such
individuals have a point mutation in FUT3, which results in its
inability to fucosylate in the a1-4 position. As shown in Fig.4G,
PMNs from a donor with a loss of function mutation in Fuc-T3 do
not express Lea. In contrast, PMNs from the same donor express
normal levels of Lex (Fig. 4G and H). In addition, treatment of
PMN from a Lea-negative donor with anti-Lea mAbs or MBLs did
not result in significantly increased PMN transmigration relative
to PMN treated with J10.4, an IgG binding control mAb or
control PMN not treated with any mAb (Fig. 4I). Although
targeting of Lea had no effect on PMN transmigration
across collagen, treatment of PMNs deficient in a1-4 fucosylation
with mAbs to Lex (which requires a1-3 and not a1-4 fucosylation
for its synthesis) did result in a large decrease in PMN
transmigration (Fig. 4I) as we have previously reported [6].
Taken together, these data highlight specific recognition of
PMN-expressed Lea trisaccharide by anti-Lea mAbs and MBLs, as
well as the functional effects of targeting Lea during PMN
transmigration.
Figure 3. Glycosyltransferases that synthesize Lea
are expressed by differentiated HL60 cells and
by human PMNs. (A) Schematic outlining the
glycosyltransferases required for Lea synthesis.
PCR (B) and real-time PCR (C) analyses show
increased expression of b3Galt1, b3Galt4, and
FUT3 in differentiated (Dif) vs. nondifferentiated
(ND) HL60 cells. Real-time PCR results are
depicted as the fold change relative to ND HL60s
and are normalized for expression of the house-
keeping gene GAPDH. Data are means 6 SE from
n = 4 HL60 differentiation assays. ***P , 0.001.
(D) Immunoblots showing increased protein
expression of b3Galt4 and FUT3 in Dif (D) vs.
ND HL60 cells. Blots are representative from n =
4 HL60 differentiation assays. PCR (E) and
immunoblotting (F) analyses demonstrate expres-
sion of FUT3 and b3Galt4 in human PMN. As a
control for removal of eosinophils expression of
MBP, an eosinophil marker was also examined.
Data shown are representative of results obtained
from n = 5 independent blood donors.
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Figure 4. Engagement of PMN Lea increases TEM and transmigration. (A) Anti-Lea mAbs 7LE (10 mg/ml) and SPM522 (10 mg/ml) and the Lea-biding
lectin MBL (10 mg/ml) increase PMN TEM to the chemoattractant fMLF (100 nM) across T84 IECs relative to IgG or lectin controls. Data shown are
means 6 SE using PMNs from n = 5 independent donors. ***P , 0.001. (B) Immunoblot demonstrating expression of Lea in T84, but not Caco2, IECs.
Data shown are representative of n = 3 Western blots. (C) Confluent T84 or Caco2 monolayers were costained with 10 mg/ml anti-ZO1 (green) or
10 mg/ml anti Lea mAb 7LE (red). Protein localization was determined by confocal microscopy analysis. Representative images from n = 3 experiments
are shown both en face and in the x–z plane of the section. (D) Anti-Lea mAbs 7LE (10 mg/ml) and SPM522 (10 mg/ml) and the Lea-biding lectin
MBL (10 mg/ml) increase PMN TEM to fMLF (100 nM) across Caco2 IECs. Data are means 6 SE from n = 3 blood donors. ***P , 0.001. Engagement
of Lea increases PMN transmigration across collagen-coated transwells to fMLF (100 nM) (E) or IL-8 (100 nM) (F). Data are means 6 SE from n = 5 blood
donors. ***P , 0.001; **P , 0.01. (G) Flow plot of PMN from a Lea-negative blood donor comparing surface expression of Lea (blue) and Lex (red),
relative to an IgG control (gray). (H) Quantification of flow-plot data showing lack of surface expression of Lea in the PMN from a Lea-negative donor.
(I) No effect on PMN transmigration across collagen-coated transwells to 100 nm fMLF was observed when PMN from a Lea-negative donor were treated
with 10 mg/ml anti-Lea mAbs (7LE/SPM522) or 10 mg/ml MBLs. Ctrl, control.
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DISCUSSION
Although PMN migration into mucosal tissues is essential for
effective host defense against invading pathogens, dysregulated
PMN migration is implicated in the pathology of many chronic
inflammatory conditions, including rheumatoid arthritis, myo-
cardial reperfusion injury, chronic obstructive pulmonary dis-
ease, and inflammatory bowel disease [24–28]. Recent evidence
has shown that migration of PMNs into epithelial-lined organs,
such as the intestine, is, in part, regulated through glycan-
mediated adhesion events. For example, we have demonstrated
that mAb targeting of sLea on the epithelial protein CD44v6
blocks PMN TEM into the intestinal lumen [4, 5] and that
targeting of the related PMN-expressed Lewis glycan Lex also
blocks PMN TEM [6].
Blood group Ags, including ABH Ags and Lea/Leb, represent
glycan residues attached at the nonreducing ends of glycocon-
jugates, which have fundamental roles in mammalian cell-to-cell
communications at sites of inflammation [7–11]. Although it has
been previously demonstrated that human PMNs express type 2
Lewis glycans (Lex and sLex) [3, 20, 29], it has also been
previously reported that PMNs do not express the related Lewis
glycans sLea [5] and Leb [6]. Additionally, it has been reported
that Lea is expressed by inflamed and noninflamed intestinal
epithelium [21, 22]. However, to date, there have been no
studies, to our knowledge, looking at expression of Lea by PMNs.
Given the important role of Lex, sLex, and sLea in regulating
PMN trafficking, we examined expression of Lea in human
PMNs and demonstrated expression of several Lea-containing,
N-linked glycoproteins. Consistent with that, generation of
N-glycan–linked Lea has been reported previously in other cell
types [30, 31]. In addition to PMN-expressed Lea, expression of
Lea in noninflamed and inflamed mucosal epithelial tissue, as
well as in T84 model IECs, was observed in the current study.
Consistent with these data, there is a report of Lea expression in
the mucosa from individuals with ulcerative colitis that
compared the extent of epithelial Lea staining between
inflammatory lesions and adjacent noninflammatory mucosal
regions [21, 22]. Although the purpose of these studies was
to evaluate differences in Lea expression in mucosal
epithelial cells, immunohistochemistry images appear to
contain Lea-positive immune cells infiltrating the inflamed
mucosa of patients with ulcerative colitis [21].
Although the above publications reported Lea expression in
IECs, this study is the first, to our knowledge, to report expression
of Lea by human PMNs. Furthermore, this study demonstrates
that specific engagement of Lea results in enhanced PMN
transmigration. Because regulatory functions of glycans are often
mediated through interactions with complementary GBPs that
have carbohydrate-recognition domains binding specific group-
ings of 2–7 terminal sugar units in precise configurations, we next
examined the specific conformations of Lea recognized by one of
the anti-Lea mAbs (7LE) used in this study.
Glycan-binding analysis revealed specific recognition by 7LE of
glycans terminating with the basic Lea trisaccharide structure. It
has recently become better appreciated that glycans at the
termini of longer oligosaccharide chains can mediate discrete
functional effects [2]. Specifically, mAb targeting of terminal Lex
at the reducing ends of glycan chains blocks PMN TEM [6]. In
addition to binding terminal Lea, glycan array analysis also
revealed binding of 7LE to terminal Lea displayed as part of a
Lea–Lea tandem-repeat oligosaccharide. Interestingly, N-linked
glycoproteins terminating with tandem Lea repeats have been
reported to bind to C type serum lectin MBL to form a complex
that has potent inhibitory activity against growth of human
colorectal cancer cells [32, 33]. The Lea–Lea binding protein
MBL is also known to have a role in innate immunity through
activation of complement in addition to functioning as an
opsonin through direct binding of pathogen glycans [34].
Finally, array analysis also revealed that there was no recogni-
tion of glycan structures containing only internal Lea structures
by 7LE, once again highlighting the importance of the specific
affinity of GBPs for terminally expressed glycan residues.
Glycan recognition by GBPs (including mAbs and lectins) is
accomplished through interactions between protein amino acid
side chains and multiple chemical moieties, including hydroxyl
groups, N acetyl groups, and carboxylic acids on glycans. The
chemical nature and stereochemical placement of each moiety
can drive GBP-mediated recognition, such that even small
differences at an atomic level are often important for binding
interactions. In keeping with the latter, there was no recognition
by the anti-Lea mAb 7LE of glycan structures very similar to Lea,
including sLea and Lex present on the version 5.1 glycan array. In
addition, 7LE failed to recognize sulfated Lea glycans present on
the array. Interestingly, sLea glycans can act as potent ligands for
E-selectin [35].
The biosynthesis of terminal glycan structures including
Lewis glycans proceeds from precursors by stepwise addition of
monosaccharide units through the actions of discrete glycosyl-
transferases. From the type 1 chain the biosynthesis of Lea
proceeds through the activities of a b3GalT and a1,4 FucT [23].
In support of Lea biosynthesis by PMN, we show that when
HL60 myelomonocytic cells are differentiated toward a PMN-
like state there is a marked increase in the expression of
b3Galt1, bGalt4 and FUT3. HL60 cells induced to differentiate
with DMSO have many of the functional characteristics of
circulating peripheral blood granulocytes such as phagocytosis,
complement receptor activity, chemotaxis and the ability to
reduce NBT. However, it has also been reported that
differentiated HL60 cells retain surface glycan features char-
acteristic of immature undifferentiated cells [36, 37]. Given
this, expression of glycosyltransferases was also examined in
isolated human PMN where robust RNA and protein expression
of both b3Galt4 and FUT3 was observed. Further, the lack of
expression of b3Galt1 observed in PMN is consistent with
previous studies reporting that differentiated HL60 cells
express glycosyltransferases that are not found in mature
circulating PMN [36].
Given the importance of glycan-mediated binding interactions
during PMN trafficking [5, 6], we examined functional conse-
quences of ligation of Lea in PMN.
We show that specific mAb targeting of Lea increases PMN
TEM across 2 well-characterized model IEC lines. Furthermore,
incubation of PMNs with the C-type serum lectin MBL, which is a
physiologic ligand of N-linked poly Lea–Lea structures [32, 33],
also resulted in increased PMN transmigration. Unlike the anti-
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Lea mAbs used in this study, MBL can recognize other non-Lea
ligands. However, specificity for MBL–Lea interactions in
mediating increased PMN TEM was highlighted by the loss of
effect of MBL (and anti-Lea mAbs) on PMN TEM in the presence
of soluble Lea trisaccharide. Although ligation of Lea results in
enhanced PMN TEM, we have previously shown that specific
targeting of Lex (the stereoisomer of Lea) blocks PMN TEM [6],
suggesting that these related Lewis glycans are on different PMN
glycoproteins that have opposing roles during TEM. Other
studies have shown that PMN Lex is displayed on the b2 integrin
CD11b/CD18 [6, 20]. However, our data support Lex and Lea
being displayed on different PMN glycoproteins because there is
no change in the surface expression of Lea after stimulation of
PMN with fMLF in contrast to a marked increase in the surface
expression of both Lex and CD11b/CD18 after PMN activation
with fMLF [6]. Analysis of CD18/CD11b (purified from human
PMN by LM2/1 immunoaffinity) by immunoblotting revealed 2
protein bands recognized by anti-CD18 and anti-CD11b mAbs
(Supplemental Fig. 2A). Further, immunoblotting of purified
CD18/CD11b with an anti-Lex mAb (H198) confirmed expres-
sion of Lex on both the CD11b and CD18 subunits. In contrast,
there was no detection of Lea on purified CD18/CD11b
consistent with Lea and Lex being displayed on different PMN
glycoproteins. Consistent with that, targeting of PMN-expressed
Lex increased phagocytosis [6], whereas ligation of Lea had no
effect on other PMN functions (Supplemental Fig. 2B and C).
In addition, increases in PMN TEM downstream of Lea
engagement (by anti-Lea mAbs or by MBL) were not mediated
through Lea-induced changes in the surface expression of
CD18/CD11b or Lex (Supplemental Fig. 2D–G). Taken together,
these data demonstrate that, in contrast to Lex, functional effects
downstream of Lea engagement are specific to PMN trafficking
and are not mediated through CD18/CD11b.
Our studies also demonstrated that epithelial-expressed Lea is
not required for an enhanced migratory response because PMN
TEM across Caco2 IECs (which do not express Lea) was also
increased downstream of engagement of PMN-expressed Lea.
This lack of expression of Lea by Caco2 is consistent with a
previous report showing no expression of FUT3 in these IECs
[5]. Consistent with the role of PMN-expressed Lea mediating
increased PMN trafficking, engagement of PMN Lea also resulted
in increased PMN trafficking across collagen-coated support
filters, an effect that was lost using PMN from a Lea-deficient
individual. Because FUT3 encodes the a1-3/4 fucosyltransferase
required to synthesize Lea, homozygotic carriers of 1 of several
point mutations that inactivate FUT3 lack Lea Ags and, as such,
are denoted as Lewis-negative individuals (constituting about 5%
of the white population) [38, 39]. Consistent with specific mAb/
MBL targeting of PMN Lea mediating functional effects observed
during PMN TEM, treatment of PMN from an individual
incapable of a1-4 fucosylation (that do not express Lea on their
surface) with anti-Lea mAbs/Lea binding lectin did not result in
significantly increased PMN transmigration.
Highlighting the relevance of glycans to mucosal inflamma-
tion, it has been previously reported that frequencies of FUT3
polymorphisms are higher in patients with ulcerative colitis than
in healthy controls. Furthermore, stratified analyses indicate that
mutant alleles of FUT3 are more common in patients with distal
colitis than in those with more extensive colitis [21]. In addition,
although the precise etiology of inflammatory bowel disease is
not yet fully understood, abnormal host–microbial interactions
have been implicated in disease pathogenesis. Interestingly, it has
been reported that terminal Lewis Ags (including Lea) can act as
binding sites for invading microbes, including Helicobacter pylori,
Campylobacter jejuni, norovirus, and rotavirus [40–42]. Indeed,
reports have already shown that Lea-negative individuals lack
attachment factors for most norovirus strains and are thus less
prone to norovirus infection [43, 44]. Therefore, the expression
of Lea on human PMNs could have important implications for
host immune responses beyond PMN trafficking during intestinal
inflammation. Deeper understanding of the interactions be-
tween specific glycans (including Lea) and GBPs will likely lead to
new insights into, and understanding of, human disease and,
thus, has great potential to uncover novel mechanism-based anti-
inflammatory therapeutics.
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